- Report
- December 2022
Moldova
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Malta
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Ireland
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Iceland
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Hungary
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Portugal
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Poland
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Albania
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Bulgaria
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Russia
From €2252EUR$2,500USD£1,987GBP
- Report
- December 2022
Romania
From €2252EUR$2,500USD£1,987GBP
- Book
- October 2012
- 1570 Pages

The Adenovirus market is a segment of the Infectious Disease Testing market. It is used to detect the presence of adenoviruses, which are a group of viruses that can cause a range of illnesses, from the common cold to more serious respiratory, eye, and gastrointestinal infections. Adenovirus testing is used to diagnose and monitor the progression of these illnesses, as well as to detect the presence of adenoviruses in donated blood and organs. Tests are available in both laboratory-based and point-of-care formats, and can be used to detect the presence of multiple adenoviruses at once.
Some companies in the Adenovirus market include Abbott, Bio-Rad Laboratories, Hologic, Luminex, Qiagen, Roche, and Thermo Fisher Scientific. Show Less Read more